These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 27823792)

  • 21. Apixaban-induced liver injury.
    Machlab S; Miquel M; Vergara M; Escoda MR; Casas M
    Rev Esp Enferm Dig; 2019 Feb; 111(2):161-163. PubMed ID: 30569731
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Apixaban-induced cutaneous hypersensitivity: a case series with evidence of cross-reactivity.
    Isaq NA; Vinson WM; Rahnama-Moghadam S
    Dermatol Online J; 2020 Oct; 26(10):. PubMed ID: 33147679
    [No Abstract]   [Full Text] [Related]  

  • 23. Key Points to Consider When Evaluating Andexxa for Formulary Addition.
    Peled H; Dau NQ; Lau H
    Neurocrit Care; 2020 Aug; 33(1):20-24. PubMed ID: 31641937
    [No Abstract]   [Full Text] [Related]  

  • 24. [Repeated Cerebellar Hemorrhage Related to Rivaroxaban and Apixaban: A Case Report].
    Yokoi M; Toyama Y; Tsurusaki Y; Nakamura A; Mima Y; Kuwashiro T; Wakugawa Y; Yasaka M; Okada Y
    Brain Nerve; 2016 May; 68(5):573-7. PubMed ID: 27156511
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Embolic stroke during apixaban therapy for left atrial appendage thrombus.
    Ohyagi M; Nakamura K; Watanabe M; Fujigasaki H
    J Stroke Cerebrovasc Dis; 2015 Apr; 24(4):e101-2. PubMed ID: 25620711
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Plasma Exchange for Urgent Apixaban Reversal in a Case of Hemorrhagic Tamponade after Pacemaker Implantation.
    Lam WW; Reyes MA; Seger JJ
    Tex Heart Inst J; 2015 Aug; 42(4):377-80. PubMed ID: 26413023
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Spontaneous Hemopericardium in a Patient Receiving Apixaban Therapy: First Case Report.
    Sigawy C; Apter S; Vine J; Grossman E
    Pharmacotherapy; 2015 Jul; 35(7):e115-7. PubMed ID: 26095120
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Managing Nonoperable Intracranial Bleeding Associated With Apixaban: A Series of 2 Cases.
    Faust AC; Tran DM; Lo C; Lai S; Sheperd L; Liu M; Denetclaw T
    J Pharm Pract; 2018 Feb; 31(1):107-111. PubMed ID: 29278991
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Warfarin and Newer Agents: What the Oral Surgeon Needs to Know.
    Steed MB; Swanson MT
    Oral Maxillofac Surg Clin North Am; 2016 Nov; 28(4):515-521. PubMed ID: 27624772
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Case Report: Apixaban-Associated Gluteal Artery Extravasation Reversed With PCC3 Without FFP.
    Denetclaw TH; Tam J; Arias V; Kim R; Martin C
    J Pharm Pract; 2016 Aug; 29(4):427-30. PubMed ID: 26519251
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Andexanet Alfa for the Reversal of Factor Xa Inhibitor Activity.
    Siegal DM; Curnutte JT; Connolly SJ; Lu G; Conley PB; Wiens BL; Mathur VS; Castillo J; Bronson MD; Leeds JM; Mar FA; Gold A; Crowther MA
    N Engl J Med; 2015 Dec; 373(25):2413-24. PubMed ID: 26559317
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Andexanet Alfa: Considerations and Practical Applications.
    Owusu KA; Effendi MK; DeFilippo NA; Reardon DP; Ian Lee A
    Crit Pathw Cardiol; 2019 Dec; 18(4):200-206. PubMed ID: 31725512
    [No Abstract]   [Full Text] [Related]  

  • 33. Quick reference guide to apixaban.
    Hurst KV; O'Callaghan JM; Handa A
    Vasc Health Risk Manag; 2017; 13():263-267. PubMed ID: 28744136
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Efficacy and safety of apixaban in the patients undergoing the ablation of atrial fibrillation.
    Nagao T; Inden Y; Shimano M; Fujita M; Yanagisawa S; Kato H; Ishikawa S; Miyoshi A; Okumura S; Ohguchi S; Yamamoto T; Yoshida N; Hirai M; Murohara T
    Pacing Clin Electrophysiol; 2015 Feb; 38(2):155-63. PubMed ID: 25487164
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cardiology Patient Pages: Antidotes for Bleeding Caused by Novel Oral Anticoagulants.
    Pollack CV
    Circulation; 2016 Jan; 133(2):e18-9. PubMed ID: 27028439
    [No Abstract]   [Full Text] [Related]  

  • 36. Oral apixaban for the treatment of venous thromboembolism in cancer patients: results from the AMPLIFY trial.
    Agnelli G; Buller HR; Cohen A; Gallus AS; Lee TC; Pak R; Raskob GE; Weitz JI; Yamabe T
    J Thromb Haemost; 2015 Dec; 13(12):2187-91. PubMed ID: 26407753
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Extended anticoagulation with apixaban reduces hospitalisations in patients with venous thromboembolism. An analysis of the AMPLIFY-EXT trial.
    Liu X; Thompson J; Phatak H; Mardekian J; Porcari A; Johnson M; Cohen AT
    Thromb Haemost; 2016 Jan; 115(1):161-8. PubMed ID: 26446706
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pharmacology and laboratory testing of the oral Xa inhibitors.
    Samama MM; Meddahi S; Samama CM
    Clin Lab Med; 2014 Sep; 34(3):503-17. PubMed ID: 25168939
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Apixaban versus enoxaparin in elective major orthopedic surgery: a clinical review.
    Maniscalco P; Caforio M; Imberti D; Porcellini G; Benedetti R
    Clin Appl Thromb Hemost; 2015 Mar; 21(2):115-9. PubMed ID: 25125051
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Efficacy and safety of apixaban compared with aspirin in the elderly: a subgroup analysis from the AVERROES trial.
    Ng KH; Shestakovska O; Connolly SJ; Eikelboom JW; Avezum A; Diaz R; Lanas F; Yusuf S; Hart RG
    Age Ageing; 2016 Jan; 45(1):77-83. PubMed ID: 26590293
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.